Congresses

Low immunogenicity of emicizumab in persons with haemophilia A

Schmitt C, Emrich T, Asikanius E, et al. Poster presentation ABS141.

Go to Document

Safety and efficacy of emicizumab in persons with haemophilia A with/without FVIII inhibitors: Pooled data from four phase III studies (HAVEN 1–4)

Callaghan MU, Négrier C, Paz-Priel I, et al. Poster presentation ABS192.

Go to Document

Evaluating the economic burden associated with problem joints, across moderate and severe haemophilia A, in children and adults: CHESS Paediatrics and CHESS II

Chowdary P, Hermans C, Asghar S, et al. Poster presentation ABS1148.

Go to Document

Improvement in annualized bleed rate in patients with hemophilia A initiating emicizumab – physician reported outcomes from the Adelphi Hemophilia A Disease Specific Programme

Khairnar R, Decker-Palmer M, Mellor J, et al. ASH 2021; Poster presentation 1961.

Go to Document

Characterizing mild and moderate hemophilia A patients in the real world: A patient-centric approach

Witkop M, Xu T, Hanson G, et al. ASH 2021; Poster presentation 2107.

Go to Document

Evaluation of the safety of emicizumab prophylaxis in persons with hemophilia A: An updated summary of thrombotic events and thrombotic microangiopathies

Howard M, McKinley D, Sanabria F, et al. ASH 2021; Poster presentation 3186.

Go to Document

A novel methodology for building longitudinal, patient-centric real world datasets in hemophilia A

Skinner MW, Hanson G, Xu T, et al. ASH 2021; Oral presentation 594.

Go to Document

Emicizumab prophylaxis in persons with hemophilia A, aged ≥50 years, with comorbidities – pooled data from four phase III studies (HAVEN 1, 3, and 4, and STASEY)

Jiménez-Yuste V, Oldenburg J, Tzeng E, et al. ASH 2021; Poster presentation 2103.

Go to Document

An early view analysis of characteristics of persons with hemophilia Atreated with emicizumab using secondary claims data

Mahajerin A, Yang E, Patel AM, et al. Poster presentation.

Go to Document

Changes in healthcare resource use and costs after emicizumab initiation for hemophilia A

Mahajerin A, Khairnar R, Meyer CS, et al. Poster presentation.

Go to Document

Complications associated with central venous acceess devices in patients with hemophilia A: a secondary claims-base analysis

Orji C, Khairnar R, Patel AM, et al. Poster Presentation.

Download PDF

Summary of thromboembolic (TE) or thrombotic microangiopathy (TMA) events in persons taking emicizumab

Lee L, Moreno K, Kuebler P, et al. Oral presentation P131.

Go to Document

Final analysis of the STASEY trial: a single-arm, multicenter, open-label, Phase III clinical trial evaluating the safety and tolerability of emicizumab prophylaxis in persons with hemophilia A with factor VIII inhibitors

Jiménez-Yuste V, Peyvandi F, Klamroth R, et al. ISTH 2021; Poster presentation PB0521.

Go to Document

Bone and joint health markers in persons with hemophilia A treated with emicizumab in HAVEN 3

Kiialainen A, Niggli M, Kempton C, et al. Oral presentation.

Go to Document

Real-world treatment patterns, health outcomes, and healthcare resource use among persons with hemophilia A

Caplan EO, Patel AM, DeClue R, et al. Poster presentation 15.

Go to Document

An insight into clinical outcomes in mild, moderate, and severe hemophilia A (HA): A preliminary analysis of the CHESS II study

Nissen F, Burke T, Asghar S, et al. Oral presentation OC 09.3.

Go to Document

Effect of moderate and severe hemophilia A on daily life in children and their caregivers: A CHESS Paediatrics Study analysis

Khair K, Nissen F, Silkey M, et al. Oral presentation 147.

Go to Document

Emicizumab prophylaxis in persons with mild or moderate hemophilia A: Results from the interim analysis of the HAVEN 6 study

Négrier C, Mahlangu J, Lehle M, et al. ASH 2021; Oral presentation 343.

Go to Document

Surgical experience from four phase III studies (HAVEN 1–4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors

Santagostino E, Oldenburg J, Chang T, et al. Oral presentation OC 60.1.

Go to Document

Patient access to hemophilia A treatment varies across US commercial health plans

Margaretos NM, Patel AM, Pranzer AD, et al. Poster presentation.

Download PDF

Timing of treated spontaneous bleeding in persons with haemophilia A receiving emicizumab prophylaxis 6 mg/kg once every 4 weeks

Pipe SW, Ko RH, Chang T, et al. Poster presentation P191.

Go to Document

Association of physical activity with bleeding frequency in children with hemophilia A: a CHESS PAEDs study analysis

Ofori-Asenso R, Nissen F, Silkey M, et al. ISTH 2021; Poster presentation PB0512.

Go to Document

Estimating the risk of myocardial infarction in persons with hemophilia A using a machine-learning approach with US claims data

Faghmous I, Flores C, Sarouei K, et al. Poster presentation P-1133.

Go to Document

Surgical experience from the Phase III STASEY trial of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors: Data from the second interim analysis

Castaman G, Kremer Hovinga JA, Schutgens R, et al. Poster presentation PB0939.

Go to Document

An analysis of fatalities in persons with congenital hemophilia A reported in the FDA Adverse Event Reporting System (FAERS) database

De Ford C, Kuebler P, Shang A, et al. Poster presentation 25.

Go to Document

Real-world persistence with and adherence to emicizumab prophylaxis in persons with hemophilia A: a secondary claims database analysis

Mahajerin A, Khairnar R, Meyer CS, et al. Poster presentation 866.

Go to Document

Emicizumab outcomes in hemophilia A using real-world data from the Canadian Hemophilia Bleeding Disorder Registry

Poon M-C, Lee A, Germini F, et al. ASH 2021; Oral presentation 347.

Go to Document

Emicizumab treatment is efficacious and well tolerated long term in persons with haemophilia (PwHA) with or without FVIII inhibitors: Pooled data from four HAVEN studies

Callaghan M, Negrier C, Paz-Priel I, et al. Oral presentation OC 60.2.

Go to Document

A survey study of hematologists in the United States to understand disease management of patients with hemophilia A treated with emicizumab

Owens WE, Patel AM, Poulos K, et al. Poster presentation P205.

Go to Document

Emicizumab in obese adults with hemophilia A - pooled data from three Phase III studies (HAVEN 1, 3 and 4)

Recht M, Mahlangu J, Minhas M, et al. ISTH 2021; Poster presentation PB0435.

Go to Document

Factor VIII use in the treatment of breakthrough bleeds in hemophilia A patients without inhibitors on emicizumab prophylaxis: the phase 3 HAVEN 3 study experience

Callaghan M, Trzaskoma B, Ko RH, et al. Poster presentation P-2395.

Go to Document

A contemporary framework for understanding mortality in people with congenital hemophilia A (PwcHA)

Pipe SW, Kruse-Jarres R, Mahlangu JN, et al. Poster presentation 23.

Go to Document

Pharmacokinetics and coagulation biomarkers in persons with hemophilia A (PwHA) and FVIII inhibitors receiving emicizumab in the Phase IIIb STASEY study

Kiialainen A, Petry C, Jiménez-Yuste V, et al. Poster presentation PB0942.

Go to Document

A phase IV, multicenter, open-label study of emicizumab prophylaxis in persons with hemophilia A with or without FVIII inhibitors undergoing minor surgical procedures

Escobar M, Dunn A, Quon D, et al. Poster presentation 1786.

Go to Document

Surgical experience from the phase III STASEY trial of emicizumab prophylaxis in persons with hemophilia A with FVIII inhibitors: Final analysis

Castaman G, Windgya J, Alzahrani H, et al. ASH 2021; Oral presentation 344.

Go to Document

A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): Interim analysis results

Jiménez-Yuste V, Klamroth R, Castaman G, et al. Oral presentation OC 60.3.

Go to Document

Estimating the burden of intracranial hemorrhage in persons with hemophilia A using administrative claims data.

Mahajerin A, Patel AM, Yang E, et al. Poster presentation P-2398.

Go to Document

Associations between physical activity levels and bleeding frequency in people with mild, moderate, and severe hemophilia A (HA): A preliminary analysis of the CHESS II study

Nissen F, Burke T, Asghar S, et al. Poster presentation PB0943.

Go to Document

Characteristics of persons with hemophilia A treated with emicizumab with or without factor VIII inhibitors

Mahajerin A, Yang E, Patel AM, et al. Poster presentation 31.

Go to Document

Analysis of hemophilia A outcomes and treatment patterns using real-world data from the Canadian Hemophilia Bleeding Disorder Registry

Lee A, Germini F, Poon M, et al. Poster presentation 1793.

Go to Document

Association of hemophilia A inhibitor status and patient-reported outcomes with work productivity and health-related quality of life

Ullman MM, Manco-Johnson MJ, Roberts JC, et al. ASH 2021; Poster presentation 4069.

Download PDF

Joint bleeds in paediatric patients with haemophilia A: A CHESS study analysis

Castro FA, Silkey M, Khair K, et al. Oral presenation OC 70.1.

Go to Document

A systematic review of mortality statistics and causes of death in people with congenital hemophilia A (PwcHA)

Hay CR, Nissen F, Pipe SW. Poster presentation 32.

Go to Document

Long-term safety and efficacy for up to >5 years in a phase 1/2 study in patients with severe hemophilia A

Shima A, Nagao A, Taki M, et al. Poster presentation PB0950.

Download PDF

Safety and efficacy of emicizumab in persons with hemophilia A with or without FVIII inhibitors: pooled data from four phase III studies (HAVEN 1–4)

Callaghan MU, Négrier C, Paz-Priel I, et al. Poster presentation 1800.

Go to Document

Trends in prescribing practices for management of hemophilia

Curtis R, Roberts JC, Crook N, et al. ASH 2021; Oral Presentation 2112.

Download PDF

Analytical performance evaluation of a dedicated calibrator and controls for emicizumab quantification

Ramamurthy N, Kucharski C, McInerney M, et al. Oral presentation OC 07.4.

Go to Document

Summary of thrombotic events or thrombotic microangiopathy events in persons taking emicizumab

Lee L, Moreno K, Kuebler P, et al. Poster presentation 35.

Go to Document

A randomized, multicenter, open-label, Phase III clinical trial to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in persons with hemophilia A in the Asia-Pacific region (HAVEN 5)

Wang S, Zhao X, Wang X, et al. Poster presentation PB0957.

Go to Document

Problem joints and their clinical and humanistic burden in children and adults with moderate and severe hemophilia A: CHESS Paediatrics and CHESS II

McLaughlin P, Hermans C, Asghar S, et al. Poster presentation 2532.

Go to Document

Early patient experiences with emicizumab in the United States: a qualitative study

Markowitz JT, Patel AM, Raimundo K, et al. Poster presentation PB0244.

Go to Document

Second interim analysis results from the STASEY trial: A single-arm, multicenter, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in people with hemophilia A (PwHA) with FVIII inhibitors.

Jiménez-Yuste V, Klamroth R, Castaman G, et al. Poster presentation PB0958.

Go to Document

Bone and joint health markers in persons with hemophilia A (PwHA) treated with emicizumab in the HAVEN 3 clinical trial

Kiialainen A, Niggli M, Kempton C, et al. Poster presentation 36.

Go to Document

Real-world safety of emicizumab: The first interim analysis of the European Haemophilia Safety Surveillance (EUHASS) Database

Shang A, Bienz NS, Gadiraju R, et al. Poster presentation 2685.

Go to Document

Evaluating patient and caregiver treatment preferences in hemophilia A using a discrete choice experiment

Benton M, Shi L, Patel AM, et al. Poster presentation PB0245.

Go to Document

An insight into the impact of hemophilia A on daily life according to disease severity: A preliminary analysis of the CHESS II study

Noone D, Nissen F, Xu T, et al. Poster presentation 3449.

Go to Document

Health-related quality of life in paediatric patients with haemophilia A

Castro FA, Silkey M, Khair K, et al. Poster presentation PB0250.

Go to Document

Impact of hemophilia A inhibitor on joint health and health-related quality of life from the Hemophilia Utilization Group Studies Part VIII in the US

Ullmann MM, Manco-Johnson MJ, Roberts JC, et al. Poster presentation 3457.

Go to Document

Exposure–response modeling of emicizumab for the prophylaxis of bleeding in haemophilia A patients with and without inhibitors against factor VIII

Jonsson F, Schmitt C, Petry C, et al. Poster presentation PB0325.

Go to Document

Timing of treated spontaneous bleeding in persons with haemophilia A (PwHA) in the HAVEN 3 study

Mahlangu J, Oldenburg J, O'Connell N, et al. Poster presentation PB0694.

Go to Document

Emicizumab prophylaxis improves long-term physical health scores in persons with haemophilia A (PwHA) with and without inhibitors: update from the HAVEN 3 and HAVEN 4 studies

Skinner M, Negrier C, Paz-Priel I, et al. Poster presentation PB0698.

Go to Document

Treatment patterns and outcomes in persons with hemophilia A (PwHA): Analysis from the CHOICE survey in the United States

Patel AM, Cyhaniuk A, Raimundo K, et al. Poster presentation PB1404.

Go to Document

Emicizumab pediatric experience in clinical studies and beyond

Levy G. Oral Presentation.

Go to Document

Factor VIII use in the treatment of breakthrough bleeds in persons with hemophilia A without inhibitors on emicizumab prophylaxis: The phase III HAVEN 3 study experience

Callaghan M, Trzaskoma B, Ko RH, et al. Poster presentation.

Go to Document

Early patient experiences with emicizumab in the United States: a qualitative study

Markowitz JT, Patel AM, Raimundo K, et al. Poster presentation.

Go to Document

Congresses

The below Genentech/Roche-sponsored congress posters and oral presentations include data presented at scientific meetings from mid-2019 onwards. Click the below links for congress publications of interest.